Sivik Global Healthcare LLC Sells 12,000 Shares of Danaher Corporation $DHR

Sivik Global Healthcare LLC reduced its holdings in Danaher Corporation (NYSE:DHR) by 34.3% in the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 23,000 shares of the conglomerate’s stock after selling 12,000 shares during the period. Danaher makes up 1.5% of Sivik Global Healthcare LLC’s portfolio, making the stock its 14th largest holding. Sivik Global Healthcare LLC’s holdings in Danaher were worth $5,265,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also made changes to their positions in the company. Tyche Wealth Partners LLC purchased a new stake in shares of Danaher in the third quarter worth approximately $462,000. Bank Pictet & Cie Europe AG grew its stake in Danaher by 25.4% in the 4th quarter. Bank Pictet & Cie Europe AG now owns 366,481 shares of the conglomerate’s stock worth $83,895,000 after acquiring an additional 74,301 shares in the last quarter. Lockheed Martin Investment Management Co. lifted its stake in Danaher by 49.4% in the third quarter. Lockheed Martin Investment Management Co. now owns 25,340 shares of the conglomerate’s stock worth $5,024,000 after acquiring an additional 8,380 shares during the period. Johnson Investment Counsel Inc. lifted its stake in Danaher by 2.9% in the third quarter. Johnson Investment Counsel Inc. now owns 664,705 shares of the conglomerate’s stock worth $131,784,000 after acquiring an additional 18,744 shares during the period. Finally, Resona Asset Management Co. Ltd. lifted its stake in Danaher by 4.6% in the third quarter. Resona Asset Management Co. Ltd. now owns 513,288 shares of the conglomerate’s stock worth $100,071,000 after acquiring an additional 22,595 shares during the period. 79.05% of the stock is owned by hedge funds and other institutional investors.

Danaher Stock Down 0.6%

Shares of NYSE:DHR opened at $191.03 on Wednesday. The business has a 50-day moving average price of $202.70 and a 200 day moving average price of $214.59. The company has a current ratio of 1.87, a quick ratio of 1.51 and a debt-to-equity ratio of 0.35. The company has a market capitalization of $135.19 billion, a price-to-earnings ratio of 37.90, a PEG ratio of 2.59 and a beta of 0.95. Danaher Corporation has a 12-month low of $171.00 and a 12-month high of $242.80.

Danaher (NYSE:DHR) last released its quarterly earnings results on Tuesday, January 27th. The conglomerate reported $2.23 EPS for the quarter, topping the consensus estimate of $2.14 by $0.09. Danaher had a return on equity of 10.81% and a net margin of 14.71%.The business had revenue of $6.84 billion during the quarter, compared to analyst estimates of $6.79 billion. During the same period last year, the business posted $2.14 earnings per share. The company’s quarterly revenue was up 4.6% on a year-over-year basis. Sell-side analysts expect that Danaher Corporation will post 7.63 EPS for the current year.

Danaher Increases Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, April 24th. Investors of record on Friday, March 27th will be issued a $0.40 dividend. This represents a $1.60 annualized dividend and a yield of 0.8%. This is a boost from Danaher’s previous quarterly dividend of $0.32. The ex-dividend date of this dividend is Friday, March 27th. Danaher’s dividend payout ratio is currently 31.75%.

Insider Buying and Selling

In other Danaher news, EVP Gregory M. Milosevich sold 1,320 shares of the firm’s stock in a transaction on Thursday, February 19th. The stock was sold at an average price of $208.01, for a total value of $274,573.20. Following the sale, the executive vice president directly owned 5,099 shares in the company, valued at $1,060,642.99. This trade represents a 20.56% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. 11.20% of the stock is owned by company insiders.

Wall Street Analysts Forecast Growth

A number of analysts recently weighed in on DHR shares. TD Cowen reaffirmed a “buy” rating on shares of Danaher in a research note on Wednesday, January 7th. Jefferies Financial Group upped their price objective on Danaher from $255.00 to $265.00 and gave the stock a “buy” rating in a research note on Wednesday, January 28th. Robert W. Baird set a $251.00 price target on shares of Danaher in a report on Thursday, January 29th. Leerink Partners lifted their price target on shares of Danaher from $260.00 to $270.00 and gave the stock an “outperform” rating in a report on Friday, January 16th. Finally, KeyCorp reaffirmed an “overweight” rating on shares of Danaher in a report on Thursday, January 29th. Seventeen equities research analysts have rated the stock with a Buy rating and three have given a Hold rating to the company’s stock. According to data from MarketBeat.com, Danaher has an average rating of “Moderate Buy” and a consensus price target of $253.79.

Danaher Profile

Danaher Corporation (NYSE: DHR) is a global science and technology company that designs, manufactures and markets products and services for the life sciences, diagnostics, and environmental and applied markets. The company organizes its operations into business segments focused on Life Sciences, Diagnostics, and Environmental & Applied Solutions, supplying instruments, reagents, software and related services that support research, clinical testing, biopharmaceutical development, and industrial and environmental monitoring.

Products and services in Danaher’s portfolio include analytical and diagnostic instruments, laboratory consumables and reagents, digital and software solutions for workflow and data management, field and industrial monitoring equipment, and service and maintenance programs.